Navigation Links
Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Date:3/23/2009

SAN DIEGO, March 23 /PRNewswire/ -- Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced that it is conducting a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) NPI-2358 in combination with standard chemotherapy (docetaxel) in patients with non-small cell lung cancer (NSCLC). This study follows on positive outcomes in the Phase 1 study assessing the safety, pharmacokinetics and efficacy of the combination.

Preclinical and clinical data suggest that VDAs may be complementary or synergistic with chemotherapeutics and anti-angiogenesis agents due to the different targets and mechanisms of action. In addition, the non-overlapping side effect profile of VDAs compared to most other anti-cancer treatments makes them ideal candidates to employ in new combination therapies. Models combining NPI-2358 with docetaxel have produced particularly positive results in both efficacy and tolerability.

The ADVANCE (Assessment of Docetaxel and Vascular Disruption in Non-Small Cell Lung Cancer) trial will assess NPI-2358 in combination with docetaxel compared to docetaxel alone in patients with NSCLC who previously failed at least one chemotherapy regimen. Overall survival will be the primary endpoint of the trial, and progression free survival and tumor response rates will be compared as secondary endpoints. Approximately 150 patients will participate in the trial at clinical trial sites in the U.S., Australia, India, and South America.

"This is an exciting time, as positive results for the combination of NPI-2358 and docetaxel appear to be translating well from the bench to the bedside. We will now be able to test the improvement in efficacy with the addition of NPI-2358 to the standard of care," said Dr. Shirish Gadgeel, M.D., Assistant Professor at the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan where the first patient to
'/>"/>

SOURCE Nereus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... interface is the device," Nobel laureate Herbert Kroemer ... be found at the junctures where layers of ... nanotechnology, the interfaces between layers of metal oxides ... high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics and ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... selected by Buffalo BioBlower Technologies LLC ("B3") as the ... Phase 2 award from the Army Corps of Engineers.  ... that kills all biological contaminants and destroys VOCs and ...
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... the only one completely confused by the Cingular merger with ... facts of the deal. Cingular Wireless acquires the assets and ... have 46 million customers, topping now No. 2 carrier Verizon ... keeps the rights to the AT&T Wireless brand and plans ...
... of the statewide Wisconsin business-plan contest this year ... survive the first round than they did during the inaugural ... initial abstracts of business ideas has passed, a panel of ... The survivors, who must write extended summaries for a further ...
... of Wisconsin-Milwaukee The director of the university's ... would leave for the University of Cincinnati in April. Professor ... feel valued, and that UW-Milwaukee does not have good ... , Menasha, Wis. Banta Corporation said it would ...
Cached Biology Technology:Cingular confusion 2Cingular confusion 3Coaching available for business-plan contest survivors 2
(Date:7/9/2014)... puzzle behind nature,s ability to split the water ... development of artificial photosynthesis for clean, green and ... collaboration of scientists led by researchers with the ... SLAC National Accelerator Laboratory. , Working at ... most powerful x-ray laser, the researchers were able ...
(Date:7/9/2014)... Guelph scientist that involved fitting bumblebees with tiny ... neonicotinoid pesticide hampers bees, ability to forage for ... professor in Guelph,s School of Environmental Sciences, and ... July 9 in the British Ecological Society,s journal ... how long-term pesticide exposure affects individual bees, day-to-day ...
(Date:7/9/2014)... With grilling season upon us, many backyard cooks are ... fatty hot dogs. But low fat can sometimes mean ... addressing the texture problem in low-fat wieners that are ... study was published in ACS, Journal of Agricultural ... colleagues note that hot-dog consumers have come to expect ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Bee foraging chronically impaired by pesticide exposure: Study 2
... ARBOR, Mich. Researchers at the University of ... techniques for head and neck cancer to avoid ... A new study shows these principles and techniques ... swallowing complications. The researchers applied highly conformal, ...
... a CD, reminded her son, Ryan, of his 4-H project when ... three beautiful squealing black and white piglets at the auction," she ... Lincoln Town Car, because we didn,t have a truck." Recordings ... him four times a day. They were part of a new ...
... The European Nucleotide Archive (ENA) is launched today, consolidating ... point to globally comprehensive DNA and RNA sequence information. ... Institute (EMBL-EBI), a part of European Molecular Biology Laboratory. ... previously unimaginable amounts of data being deposited in the ...
Cached Biology News:U-M study achieves reduced side effects in head and neck cancer treatment 2Can a mother's voice spur recovery from a coma? 2Can a mother's voice spur recovery from a coma? 3Can a mother's voice spur recovery from a coma? 4Can a mother's voice spur recovery from a coma? 5Enabling easy access to DNA sequence information 2
...
... Immunogen: Partially purified ... MA1-710 detects vitamin D receptor (VDR) ... amphibian, and fish tissues. This ... or glucocorticoid receptors. MA1-710 detects ...
... AccuPrime™ Pfx DNA Polymerase is ideal ... for downstream applications such as cloning ... provided by a proprietary enzyme preparation ... sp. with proofreading (3'Cut Site5' exonuclease) ...
... BV-10 offers precision beveling of ... 50m. The unique abrasive plate ... for greater control of the ... accomplished very rapidly and produces ...
Biology Products: